Back to Trades
Other4
HALOZYME THERAPEUTICS, INC.
HALO
Total Value
$0
Company Information
- Company Name
- HALOZYME THERAPEUTICS, INC.
- Ticker Symbol
- HALO
- CIK
- 0001159036
Insider Information
- Name
- LaBrosse Nicole
- Role
- SVP, CHIEF FINANCIAL OFFICER
- Location
- SAN DIEGO, CA
Officer
Filing Details
- Filing Date
- Feb 11, 2026
- Transaction Date
- Feb 9, 2026
- Accession Number
- 0001159036-26-000015
- Form Type
- 4
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Feb 9, 2026 | Derivative | 5,167 | — | Grant/Award | — |
| Feb 9, 2026 | Derivative | 7,448 | — | Grant/Award | — |
| Feb 9, 2026 | Derivative | 29,502 | — | Grant/Award | — |
Footnotes
- (F1)Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.
- (F2)Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.
- (F3)Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.